Hidradenitis Suppurativa: Sonelokimab Shows Promise in Study

Sonelokimab is a novel humanized nanobody that selectively binds to interleukin (IL)-17A and IL-17F.
MDedge News

source https://www.medscape.com/s/viewarticle/hidradenitis-suppurativa-sonelokimab-shows-promise-phase-2-2024a10006oj?src=rss